Alan V Boddy

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6664317/publications.pdf

Version: 2024-02-01

139	4,727	87888 38	123424 61
papers	citations	h-index	g-index

140	140	140	5800
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2008, 14, 7917-7923.	7.0	361
2	Phase I and pharmacokinetic study of d -limonene in patients with advanced cancer. Cancer Chemotherapy and Pharmacology, 1998, 42, 111-117.	2.3	198
3	Metabolism and Pharmacokinetics of Oxazaphosphorines. Clinical Pharmacokinetics, 2000, 38, 291-304.	3.5	178
4	Phase I Clinical and Pharmacokinetic Study of Pemetrexed and Carboplatin in Patients With Malignant Pleural Mesothelioma. Journal of Clinical Oncology, 2002, 20, 3533-3544.	1.6	141
5	Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. British Journal of Cancer, 2016, 114, 723-730.	6.4	132
6	Curcumin as a clinically-promising anti-cancer agent: pharmacokinetics and drug interactions. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 953-972.	3.3	125
7	Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochemical Pharmacology, 1994, 47, 1157-1163.	4.4	113
8	Temozolomide Pharmacodynamics in Patients with Metastatic Melanoma: DNA Damage and Activity of Repair Enzymes O6-Alkylguanine Alkyltransferase and Poly(ADP-Ribose) Polymerase-1. Clinical Cancer Research, 2005, 11, 3402-3409.	7.0	103
9	Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2009, 15, 3177-3183.	7.0	103
10	A Phase I and Pharmacokinetic Study of Paclitaxel Poliglumex (XYOTAX), Investigating Both 3-Weekly and 2-Weekly Schedules. Clinical Cancer Research, 2005, 11, 7834-7840.	7.0	102
11	Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group. Clinical Cancer Research, 2007, 13, 6410-6418.	7.0	101
12	Imagestream detection and characterisation of circulating tumour cells â€“ A liquid biopsy for hepatocellular carcinoma?. Journal of Hepatology, 2016, 65, 305-313.	3.7	98
13	Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma. Clinical Cancer Research, 2009, 15, 1241-1249.	7.0	75
14	Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System. Molecular Cancer Therapeutics, 2015, 14, 2735-2743.	4.1	75
15	2-[11C]Thymidine Positron Emission Tomography as an Indicator of Thymidylate Synthase Inhibition in Patients Treated With AG337. Journal of the National Cancer Institute, 2003, 95, 675-682.	6.3	67
16	Prospective Validation of Renal Functionâ€“Based Carboplatin Dosing in Children With Cancer: A United Kingdom Childrenâ€™s Cancer Study Group Trial. Journal of Clinical Oncology, 2000, 18, 3614-3621.	1.6	60
17	The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion. Cancer Chemotherapy and Pharmacology, 1995, 36, 53-60.	2.3	58
18	Stereoselectivity in pharmacokinetics: a general theory. Pharmaceutical Research, 1991, 08, 551-556.	3.5	56

#	Article	IF	Citations
19	A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin. British Journal of Cancer, 2001, 84, 1029-1035.	6.4	55
20	Population pharmacokinetics of carboplatin in children*. Clinical Pharmacology and Therapeutics, 1996, 59, 436-443.	4.7	53
21	Pharmacokinetics of Dactinomycin in a Pediatric Patient Population: a United Kingdom Children's Cancer Study Group Study. Clinical Cancer Research, 2005, 11, 5893-5899.	7.0	53
22	Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma â€“ a study of the United Kingdom Children's Cancer Study Group. British Journal of Cancer, 2007, 96, 424-431.	6.4	52
23	Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients. Cancer Chemotherapy and Pharmacology, 1992, 30, 207-211.	2.3	50
24	Cyclophosphamide Metabolism in Children with Non-Hodgkinâ€™s Lymphoma. Clinical Cancer Research, 2004, 10, 455-460.	7.0	46
25	Formulation of Biologically-Inspired Silk-Based Drug Carriers for Pulmonary Delivery Targeted for Lung Cancer. Scientific Reports, 2015, 5, 11878.	3.3	46
26	Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma. European Journal of Cancer, 2016, 55, 56-64.	2.8	46
27	Adaptive Dosing Approaches to the Individualization of 13-Cis-Retinoic Acid (Isotretinoin) Treatment for Children with High-Risk Neuroblastoma. Clinical Cancer Research, 2013, 19, 469-479.	7.0	45
28	Highâ€resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers. International Journal of Cancer, 2016, 138, 206-216.	5.1	45
29	Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cells. British Journal of Cancer, 2005, 92, 696-704.	6.4	44
30	Cisplatin pharmacokinetics in children with cancer. European Journal of Cancer, 1997, 33, 1823-1828.	2.8	43
31	A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer. British Journal of Cancer, 1997, 75, 287-294.	6.4	43
32	A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study. Clinical Cancer Research, 2015, 21, 267-273.	7.0	43
33	A Phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid. Investigational New Drugs, 1996, 14, 325-335.	2.6	41
34	Influence of antibiotics on the recovery and kinetics of Saccharomyces boulardii in rats. Pharmaceutical Research, 1991, 08, 796-800.	3.5	40
35	Individual Variation in the Activation and Inactivation of Metabolic Pathways of Cyclophosphamide. Journal of the National Cancer Institute, 1992, 84, 1744-1748.	6.3	40
36	NAD(P)H:Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 Activity and Expression in Bladder and Ovarian Cancer and Lower NRH:Quinone Oxidoreductase 2 Activity Associated with an NQO2 Exon 3 Single-Nucleotide Polymorphism. Clinical Cancer Research, 2007, 13, 1584-1590.	7.0	40

#	Article	IF	Citations
37	Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients. European Journal of Cancer, 1995, 31, 69-76.	2.8	39
38	Ifosfamide nephrotoxicity: Limited influence of metabolism and mode of administration during repeated therapy in paediatrics. European Journal of Cancer, 1996, 32, 1179-1184.	2.8	39
39	Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients. European Journal of Cancer, 1995, 31, 1804-1810.	2.8	37
40	Saturable metabolism of continuous high-dose ifosfamide with Mesna and GM-CSF: A pharmacokinetic study in advanced sarcoma patients. Annals of Oncology, 1999, 10, 1087-1094.	1.2	37
41	Adaptive dosing and platinumâ€"DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours. British Journal of Cancer, 2007, 96, 725-731.	6.4	35
42	Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3Âyears. Cancer Chemotherapy and Pharmacology, 2013, 71, 749-763.	2.3	35
43	A Retinol Isotope Dilution Equation Predicts Both Group and Individual Total Body Vitamin A Stores in Adults Based on Data from an Early Postdosing Blood Sample. Journal of Nutrition, 2016, 146, 2137-2142.	2.9	35
44	An LC/MS/MS method for stable isotope dilution studies of Î²-carotene bioavailability, bioconversion, and vitamin A status in humans. Journal of Lipid Research, 2014, 55, 319-328.	4.2	34
45	Efficiency of drug targeting: steady-state considerations using a three-compartment model. Pharmaceutical Research, 1989, 06, 367-372.	3.5	33
46	Comparative anticonvulsant potency and pharmacokinetics of (+)- and (â^')-enantiomers of stiripentol. Epilepsy Research, 1992, 12, 29-36.	1.6	33
47	Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rate. European Journal of Cancer, 2010, 46, 1841-1847.	2.8	33
48	Characterisation of the Clinical Pharmacokinetics of Actinomycin D and the Influence of ABCB1 Pharmacogenetic Variation on Actinomycin D Disposition in Children with Cancer. Clinical Pharmacokinetics, 2014, 53, 741-751.	3.5	33
49	Influence of isomerisation on the growth inhibitory effects and cellular activity of 13-cis and all-trans retinoic acid in neuroblastoma cells. Biochemical Pharmacology, 2002, 63, 207-215.	4.4	32
50	Pharmacokinetic Investigation of Imatinib Using Accelerator Mass Spectrometry in Patients with Chronic Myeloid Leukemia. Clinical Cancer Research, 2007, 13, 4164-4169.	7.0	32
51	Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo. Biochemical Pharmacology, 2013, 85, 29-37.	4.4	32
52	Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil. Cancer Chemotherapy and Pharmacology, 2014, 74, 667-674.	2.3	32
53	Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF). European Journal of Cancer, 2002, 38, 1081-1089.	2.8	31
54	Molecular targeting of retinoic acid metabolism in neuroblastoma: the role of the CYP26 inhibitor R116010 in vitro and in vivo. British Journal of Cancer, 2007, 96, 1675-1683.	6.4	30

#	Article	IF	Citations
55	Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy. Pharmacogenetics and Genomics, 2011, 21, 808-819.	1.5	30
56	Implementation of a Physiologically Based Pharmacokinetic Modeling Approach to Guide Optimal Dosing Regimens for Imatinib and Potential Drug Interactions in Paediatrics. Frontiers in Pharmacology, 2020, 10, 1672.	3.5	30
57	Estimation of glomerular filtration rate in paediatric cancer patients using 51CR-EDTA population pharmacokinetics. British Journal of Cancer, 2004, 90, 60-64.	6.4	29
58	Pharmacogenetics of genes across the doxorubicin pathway. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 1201-1210.	3.3	29
59	Plasma Retinol Kinetics and Î²-Carotene Bioefficacy Are Quantified by Model-Based Compartmental Analysis in Healthy Young Adults with Low Vitamin A Stores. Journal of Nutrition, 2016, 146, 2129-2136.	2.9	29
60	Comparison of continuous infusion and bolus administration of ifosfamide in children. European Journal of Cancer, 1995, 31, 785-790.	2.8	28
61	Ifosfamide metabolism and DNA damage in tumour and peripheral blood lymphocytes of breast cancer patients. Cancer Chemotherapy and Pharmacology, 2000, 46, 433-441.	2.3	27
62	Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer. British Journal of Clinical Pharmacology, 2016, 81, 989-998.	2.4	26
63	Chemotherapy in newborns and preterm babies. Seminars in Fetal and Neonatal Medicine, 2012, 17, 243-248.	2.3	25
64	Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a â€œEuropean Pediatric Oncology Off-patents Medicines Consortiumâ€•trial. Cancer Chemotherapy and Pharmacology, 2016, 78, 1175-1184.	2.3	25
65	Combined thin-layer chromatographyâ€”photographyâ€”densitometry for the quantification of ifosfamide and its principal metabolites in urine, cerebrospinal fluid and plasma. Biomedical Applications, 1992, 575, 137-142.	1.7	24
66	Is there scope for better individualisation of anthracycline cancer chemotherapy?. British Journal of Clinical Pharmacology, 2021, 87, 295-305.	2.4	24
67	Population Pharmacokinetic Investigation of Actinomycinâ€Ð in Children and Young Adults. Journal of Clinical Pharmacology, 2008, 48, 35-42.	2.0	23
68	Age-Dependent Pharmacokinetics of Doxorubicin in Children with Cancer. Clinical Pharmacokinetics, 2015, 54, 1139-1149.	3.5	23
69	Precision dosing of targeted anticancer drugsâ€”challenges in the real world. Translational Cancer Research, 2017, 6, S1500-S1511.	1.0	22
70	A study to determine the minimum volume of blood necessary to be discarded from a central venous catheter before a valid sample is obtained in children with cancer. Pediatric Blood and Cancer, 2007, 48, 687-695.	1.5	21
71	Relevance of Nonsynonymous CYP2C8 Polymorphisms to 13-cis Retinoic Acid and Paclitaxel Hydroxylation. Drug Metabolism and Disposition, 2010, 38, 1261-1266.	3.3	21
72	Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours. Cancer Chemotherapy and Pharmacology, 2016, 78, 209-216.	2.3	21

#	Article	IF	Citations
73	Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia. Cancer Chemotherapy and Pharmacology, 2019, 83, 693-704.	2.3	21
74	Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy. British Journal of Cancer, 1997, 76, 1466-1473.	6.4	20
75	Determination of anti-cancer drug actinomycin D in human plasma by liquid chromatographyâ€“mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 795, 237-243.	2.3	20
76	A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia. Pediatric Blood and Cancer, 2017, 64, e26351.	1.5	20
77	Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasma. Journal of Immunological Methods, 2009, 345, 106-111.	1.4	19
78	Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapy. European Journal of Cancer, 2011, 47, 1556-1563.	2.8	19
79	Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St Johnâ€™s Wort. Clinical Pharmacokinetics, 2019, 58, 911-926.	3.5	19
80	Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist Cereport (RMP-7) for the treatment of brain tumours. Cancer Chemotherapy and Pharmacology, 2000, 45, 284-290.	2.3	17
81	Cyclophosphamide metabolism in children following a 1-h and a 24-h infusion. Cancer Chemotherapy and Pharmacology, 2001, 47, 222-228.	2.3	17
82	Chemotherapy individualization. Investigational New Drugs, 2003, 21, 149-156.	2.6	17
83	Therapeutic monitoring of carboplatin dosing in a premature infant with retinoblastoma. Cancer Chemotherapy and Pharmacology, 2009, 63, 749-752.	2.3	17
84	Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients. Cancer Chemotherapy and Pharmacology, 2010, 65, 1057-1066.	2.3	17
85	Potential clinical impact of taking multiple blood samples for research studies in paediatric oncology: How much do we really know?. Pediatric Blood and Cancer, 2006, 46, 723-727.	1.5	16
86	Minimization of the Preanalytical Error in Plasma Samples for Pharmacokinetic Analyses and Therapeutic Drug Monitoring - Using Doxorubicin as an Example. Therapeutic Drug Monitoring, 2011, 33, 766-771.	2.0	16
87	In vitro and in vivo investigations of dihydropyridine-based chemical delivery systems for anticonvulsants. Pharmaceutical Research, 1991, 08, 690-697.	3.5	15
88	Comparison of nonlinear mixed-effect and non-parametric expectation maximisation modelling for Bayesian estimation of carboplatin clearance in children. European Journal of Clinical Pharmacology, 2001, 57, 297-303.	1.9	15
89	Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide. British Journal of Clinical Pharmacology, 2002, 53, 83-91.	2.4	15
90	Role of UDP-Glucuronosyltransferase Isoforms in 13-cis Retinoic Acid Metabolism in Humans. Drug Metabolism and Disposition, 2010, 38, 1211-1217.	3.3	15

#	Article	IF	Citations
91	Cyclophosphamide metabolism in children with Fanconiâ€™s anaemia. Bone Marrow Transplantation, 1999, 24, 123-128.	2.4	14
92	A Phase I and Pharmacokinetic Study of Ixabepilone in Combination with Carboplatin in Patients with Advanced Solid Malignancies. Clinical Cancer Research, 2008, 14, 8288-8294.	7.0	14
93	Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDPâ€glucuronosyltransferases. British Journal of Pharmacology, 2011, 162, 989-999.	5.4	14
94	Therapy-induced carboplatinâ€“DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tissues. Biochemical Pharmacology, 2012, 83, 69-77.	4.4	14
95	Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologicallyâ€based pharmacokinetic modelling approach. British Journal of Clinical Pharmacology, 2020, 86, 2080-2094.	2.4	14
96	Pharmacokinetically guided dosing of carboplatin in paediatric cancer patients with bilateral nephrectomy. Cancer Chemotherapy and Pharmacology, 2004, 54, 295-300.	2.3	13
97	Physiologically-Based Pharmacokinetic Predictions of the Effect of Curcumin on Metabolism of Imatinib and Bosutinib: In Vitro and In Vivo Disconnect. Pharmaceutical Research, 2020, 37, 128.	3.5	13
98	Physiologicallyâ€based pharmacokinetic model predictions of interâ€ethnic differences in imatinib pharmacokinetics and dosing regimens. British Journal of Clinical Pharmacology, 2022, 88, 1735-1750.	2.4	13
99	Pharmacokinetic and pharmacodynamic aspects of site-specific drug delivery. Advanced Drug Delivery Reviews, 1989, 3, 155-163.	13.7	11
100	Pharmacokinetics and Pharmacogenetics of 13-cis-Retinoic Acid in the Treatment of Neuroblastoma. Therapie, 2007, 62, 91-93.	1.0	11
101	Binding of sulfonamides to carbonic anhydrase: influence on distribution within blood and on pharmacokinetics. Pharmaceutical Research, 1989, 06, 203-209.	3.5	10
102	Estimation of renal function and its potential impact on carboplatin dosing in children with cancer. British Journal of Cancer, 2008, 99, 894-899.	6.4	10
103	Calpainâ€1 is associated with adverse relapse free survival in breast cancer: a confirmatory study. Histopathology, 2016, 68, 1021-1029.	2.9	10
104	Genetic variants in the HER2 gene: Influence on HER2 overexpression and loss of heterozygosity in breast cancer. European Journal of Cancer, 2016, 55, 27-37.	2.8	10
105	A population pharmacokinetic model of AT9283 in adults and children to predict the maximum tolerated dose in children with leukaemia. British Journal of Clinical Pharmacology, 2017, 83, 1713-1722.	2.4	10
106	Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a reâ€evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function. British Journal of Clinical Pharmacology, 2019, 85, 136-146.	2.4	10
107	Minimization of the Preanalytical Error in Pharmacokinetic Analyses and Therapeutic Drug Monitoring. Therapeutic Drug Monitoring, 2012, 34, 460-466.	2.0	9
108	A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours. European Journal of Cancer, 2016, 68, 1-10.	2.8	9

#	Article	IF	Citations
109	Wnt receptor gene FZD1 was associated with schizophrenia in genome-wide SNP analysis of the Australian Schizophrenia Research Bank cohort. Australian and New Zealand Journal of Psychiatry, 2020, 54, 902-908.	2.3	9
110	Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules. Annals of Oncology, 2002, 13, 399-402.	1.2	8
111	Pharmacokinetics of dabrafenib in a patient with metastatic melanoma undergoing haemodialysis. Pigment Cell and Melanoma Research, 2017, 30, 68-71.	3.3	8
112	Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide. European Journal of Cancer, 2017, 71, 15-24.	2.8	8
113	Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidence. European Journal of Cancer, 2018, 91, 56-67.	2.8	8
114	Application of a linear recirculation model to drug targeting. Journal of Pharmacokinetics and Pharmacodynamics, 1991, 19, 355-362.	0.6	7
115	Genetic Polymorphisms Affecting Cardiac Biomarker Concentrations in Children with Cancer: an Analysis from the â€œEuropean Paediatric Oncology Off-patents Medicines Consortiumâ€•(EPOC) Trial. European Journal of Drug Metabolism and Pharmacokinetics, 2020, 45, 413-422.	1.6	7
116	RMP-7. CNS Drugs, 1997, 7, 257-263.	5.9	6
117	Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer. Cancer Chemotherapy and Pharmacology, 2001, 48, 15-21.	2.3	6
118	Biliary excretion of etoposide in children with cancer. Cancer Chemotherapy and Pharmacology, 2006, 58, 415-417.	2.3	6
119	Investigating the heterogeneity of alkylating agentsâ€™ efficacy and toxicity between sexes: A systematic review and metaâ€analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE) Tj ETQq1 1 0.784314 rgBT /Ov		
120	Clinical Pharmacokinetic and Pharmacodynamic Considerations in the (Modern) Treatment of Melanoma. Clinical Pharmacokinetics, 2019, 58, 1029-1043.	3.5	6
121	All Half-Lives Are Wrong, But Some Half-Lives Are Useful. Clinical Pharmacokinetics, 2001, 40, 237-244.	3.5	5
122	Carboplatin Dosing in Infants With Retinoblastoma: A Case for Therapeutic Drug Monitoring. Journal of Clinical Oncology, 2012, 30, 3424-3424.	1.6	5
123	Towards a Model-Based Dose Recommendation for Doxorubicin in Children. Clinical Pharmacokinetics, 2017, 56, 215-223.	3.5	5
124	Physiologically based pharmacokinetic model predictions of natural product-drug interactions between goldenseal, berberine, imatinib and bosutinib. European Journal of Clinical Pharmacology, 2022, 78, 597-611.	1.9	5
125	Recent developments in the clinical pharmacology of classical cytotoxic chemotherapy. British Journal of Clinical Pharmacology, 2006, 62, 27-34.	2.4	4
126	Sources of preanalytical error in pharmacokinetic analyses â€“ focus on intravenous drug administration and collection of blood samples. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 825-838.	3.3	4

#	Article	IF	Citations
127	A Strategy to Refine the Phenotyping Approach and Its Implementation to Predict Drug Clearance: A Physiologically Based Pharmacokinetic Simulation Study. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 798-808.	2.5	4
128	Pharmacokinetics of Anticancer Drugs Used in Treatment of Older Adults With Colorectal Cancer: A Systematic Review. Therapeutic Drug Monitoring, 2019, 41, 553-560.	2.0	4
129	An evaluation of thymidine phosphorylase as a means of preventing thymidine rescue from the thymidylate synthase inhibitor raltitrexed. Cancer Chemotherapy and Pharmacology, 2006, 59, 197-206.	2.3	3
130	The role of solute carrier (SLC) transporters in actinomycin D pharmacokinetics in paediatric cancer patients. European Journal of Clinical Pharmacology, 2018, 74, 1575-1584.	1.9	3
131	Paclitaxel poliglumex. Drugs of the Future, 2007, 32, 0776.	0.1	3
132	Pharmacokinetic Consequences of Product Stereoselectivity in the Metabolism of Nafimidone: Estimation of Fraction Metabolized. Journal of Pharmaceutical Sciences, 1991, 80, 812-814.	3.3	2
133	The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 851-863.	3.3	2
134	Optimization of a clofarabineâ€based drug combination regimen for the preclinical evaluation of pediatric acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2020, 67, e28133.	1.5	2
135	Physiologically Based Pharmacokinetic Modeling Approaches for Patients With SARSâ€CoVâ€2 Infection: A Case Study With Imatinib. Journal of Clinical Pharmacology, 2022, , .	2.0	2
136	The use of pharmacokinetic models in the development and evaluation of site-specific drug delivery systems. Pest Management Science, 1990, 30, 91-95.	0.4	0
137	Response to Siegelet al.. Journal of Pharmacokinetics and Pharmacodynamics, 1991, 19, 373-374.	0.6	0
138	Dosing of Cancer Patients with Low or Absent Renal Function. Therapie, 2007, 62, 117-120.	1.0	0
139	The path to implementation of personalized medicine of aromatase inhibitors in patients with breast cancer. Pharmacogenomics, 2016, 17, 1861-1864.	1.3	0